Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients

O. Fiala, P. Ostasov, O. Sorejs, V. Liska, T. Buchler, A. Poprach, J. Finek,

. 2019 ; 11 (12) : . [pub] 20191125

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19043993

Grant support
UNCE/MED/006 Ministerstvo Školství, Mládeže a Tělovýchovy
LO1503 Ministerstvo Školství, Mládeže a Tělovýchovy
Progres Q39 Univerzita Karlova v Praze

Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19043993
003      
CZ-PrNML
005      
20200109095142.0
007      
ta
008      
200107s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers11121856 $2 doi
035    __
$a (PubMed)31769417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, alej Svobody 80, 30460 Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic.
245    10
$a Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients / $c O. Fiala, P. Ostasov, O. Sorejs, V. Liska, T. Buchler, A. Poprach, J. Finek,
520    9_
$a Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ostasov, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic.
700    1_
$a Sorejs, Ondrej $u Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, alej Svobody 80, 30460 Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic.
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300 Pilsen, Czech Republic. Department of Surgery, Medical School and University Hospital in Pilsen, Charles University, alej Svobody 80, 30460 Pilsen, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 14059 Prague, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Zluty kopec 7, 65653 Brno, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, alej Svobody 80, 30460 Pilsen, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 12 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31769417 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095511 $b ABA008
999    __
$a ind $b bmc $g 1480582 $s 1082663
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 12 $e 20191125 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a UNCE/MED/006 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a LO1503 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a Progres Q39 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20200107

Find record

Citation metrics

Archiving options